Matthew Hamilton Rosenberg’s Benitec Biopharma BNTC Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23	Closed	-$70	–	928
2023 Q3	$70	Buy	23 +1	+5%	+$3	﹤0.01%	896
2023 Q2	$91	Hold	22	–	–	﹤0.01%	908
2023 Q1	$80	Hold	22	–	–	﹤0.01%	932
2022 Q4	$65	Buy	+22	New	+$75	﹤0.01%	927
2022 Q2	–	Sell	-22	Closed	-$1K	–	792
2022 Q1	$1K	Hold	22	–	–	﹤0.01%	731
2021 Q4	$1K	Hold	22	–	–	﹤0.01%	706
2021 Q3	$1K	Buy	+22	New	+$1.45K	﹤0.01%	675

Other funds holding BNTC

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Matthew Hamilton Rosenberg's BNTC Position: Q4 2023 in Review

Matthew Hamilton Rosenberg sold out of Benitec Biopharma (BNTC) in Q4 2023, closing a stake of 23 shares — an estimated $70 sold.

Matthew Hamilton Rosenberg first reported a position in BNTC in Q3 2021 and held it in 7 quarters. The position peaked at $1K in Q1 2022. 13 funds tracked by Wall St. Rank hold BNTC as of Q4 2023.

Matthew Hamilton Rosenberg reported no remaining Benitec Biopharma position as of Q4 2023 after selling out during the quarter.
Matthew Hamilton Rosenberg sold 23 Benitec Biopharma shares in Q4 2023, an estimated $70.
Matthew Hamilton Rosenberg first reported a position in Benitec Biopharma in Q3 2021 and held it in 7 quarters.
Matthew Hamilton Rosenberg's Benitec Biopharma position peaked at $1K in Q1 2022.
13 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2023.

Based on Matthew Hamilton Rosenberg's 13F filing for Q4 2023, filed 16 Jan 2024.